Despite the widespread use of antiretroviral therapy that effectively limits viral replication, memory impairment remains a dilemma for HIV infected people. In the CNS, HIV infection of astrocytes leads to the production of the HIV-1 Nef protein without viral replication. Post mortem studies have found Nef expression in hippocampal astrocytes of people with HIV associated dementia suggesting that astrocytic Nef may contribute to HIV associated cognitive impairment even when viral replication is suppressed. To test whether astrocytic expression of Nef is sufficient to induce cognitive deficits, we examined the effect of implanting primary rat astrocytes expressing Nef into the hippocampus on spatial and recognition memory. Rats implanted unilaterally with astrocytes expressing Nef showed impaired novel location and novel object recognition in comparison with controls implanted with astrocytes expressing green fluorescent protein (GFP). This impairment was correlated with an increase in chemokine ligand 2 (CCL2) expression and the infiltration of peripheral macrophages into the hippocampus at the site of injection. Furthermore, the Nef exposed rats exhibited a bilateral loss of CA3 neurons. These results suggest that Nef protein expressed by the implanted astrocytes activates the immune system leading to neuronal damage and spatial and recognition memory deficits. Therefore, the continued expression of Nef by astrocytes in the absence of viral replication has the potential to contribute to HIV associated cognitive impairment.
Introduction
HIV/AIDS remains a global epidemic affecting over 33 million people, including 2.6 million new infections and 1.8 million deaths in 2009 (UNAIDS/WHO 2009 Global Summary) . HIV infection is associated with a spectrum of neurological disorders and opportunistic infections in the CNS. The virus quickly invades the brain and establishes a foothold predominantly in microglia and infiltrating macrophages that support viral replication, and in astrocytes that produce a limited set of viral neurotoxins (Messam and Major, 2000; Tornatore et al., 1991; Wiley et al., 1986) . In the beginning of the epidemic, 10−20% of the patients with HIV showed severe manifestations of neuropathology known as the AIDS dementia complex, characterized by low CD4, high viral loads, cognitive and motor impairments and behavioral changes (McArthur et al., 1993; Price et al., 1988) . Since the advent of combination antiretroviral therapy (cART), the incidence of dementia has declined significantly; however, milder forms of neuropathology still affect as many as 50% of HIV positive persons (Heaton et al., 2011; McArthur et al., 1999 McArthur et al., , 2003 Robertson et al., 2007) . Even though viral replication is well controlled by cART, viral proteins persist in viral reservoir areas (Popovic et al., 2005) suggesting that neurotoxic viral proteins may contribute to the continued cognitive decline. Patients with HIV associated neurocognitive disorders (HAND) show deficits in attention, behavior changes and memory impairment (McArthur et al., 1999 (McArthur et al., , 2003 Sacktor et al., 2002) . While it is known that HAND is a result of HIV infection in the brain, the roles of the various infected cell types remain an area of active investigation.
Replication in permissive cells in the brain such as microglia and perivascular macrophages induces the production of new virus and viral proteins, immune system activation and inflammation that result in neurotoxicity and cell death (Anderson et al., 2002) . HIV crosses into the brain predominantly through infected mononuclear cells (Haase, 1986; Peluso et al., 1985) which release viral particles that infect permissive cells and produce latent infection of astrocytes (Conant et al., 1994; Thompson et al., 2001; Tornatore et al., 1994) . Infection of astrocytes is widespread and the magnitude of astrocyte infection, particularly near perivascular macrophages, correlates with the severity of neuropathogenesis (Churchill et al., 2009) . Astrocytes support viral persistence in the brain during suppressive cART (Dayton, 2008) , since viral activity in astrocytes is not a target of antiretroviral treatment directed at replicating virus. Recent work showed TCF-4/ β-catenin-mediated transcriptional repression of HIV-1 is crucial to restricted repression in astrocytes (Henderson et al., 2012) . However, HIV-infected astrocytes do produce early viral proteins (Haughey and Neurobiology of Disease 49 (2013) 128-136 
